Careful patient selection needed to avoid high early mortality with immunotherapy

High 30-day mortality rates in advanced cancer patients receiving checkpoint inhibitors show there is still a need for careful selection of patients for treatment, Australian researchers have shown. Traditional chemotherapy has been associated with 30-day mortality rates of 8-18% in patients with advanced cancers and it had been hoped the more favourable side effect profile ...